GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » Float Percentage Of Total Shares Outstanding

Sera Prognostics (Sera Prognostics) Float Percentage Of Total Shares Outstanding : 76.24% (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sera Prognostics's float shares is 24.88 Mil. Sera Prognostics's total shares outstanding is 32.64 Mil. Sera Prognostics's float percentage of total shares outstanding is 76.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sera Prognostics's Insider Ownership is 9.18%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sera Prognostics's Institutional Ownership is 4.10%.


Sera Prognostics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Sera Prognostics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=24.88/32.64
=76.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sera Prognostics (Sera Prognostics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.
Executives
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc 10 percent owner 239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin officer: VP OF Q/R & HIPPA PRIV. OFF C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare officer: Chief Commercial Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109